However, the clinical efficacy of carlinibizumab in combination with albumin-bound paclitaxel as a third- or later-line regimen for patients with advanced NSCLC needs to be further confirmed due to the retrospective bias of this study. The gene discussed is ALB; the disease is non-small cell lung carcinoma.